Continued treatment of early virologic non-responder or partial responders with bulevirtide monotherapy for chronic hepatitis d leads to improvement in virologic and biochemical responses: results from an integrated analysis at week 96

HEPATOLOGY(2023)

Cited 0|Views19
No score
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined